

Paul Zolkind

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6929179/publications.pdf>

Version: 2024-02-01

17
papers

562
citations

840119

11
h-index

940134

16
g-index

20
all docs

20
docs citations

20
times ranked

1020
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	3.2	163
2	Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6012-6012.	0.8	62
3	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	3.2	49
4	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 73, 65-69.	0.8	40
5	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2186-2194.	3.2	37
6	Negative-Pressure Aerosol Cover for COVID-19 Tracheostomy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 672.	1.2	36
7	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119.	0.8	34
8	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
9	Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity. <i>Cell Reports</i> , 2018, 24, 2167-2178.	2.9	26
10	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 71, 169-176.	0.8	16
11	Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2326-2339.	3.2	16
12	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14
13	Untreated head and neck cancer: Natural history and associated factors. <i>Head and Neck</i> , 2021, 43, 89-97.	0.9	11
14	Integrating CD4 ⁺ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model. <i>Oncolmmunology</i> , 2021, 10, 1958589.	2.1	9
15	Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer. <i>IScience</i> , 2022, 25, 104216.	1.9	6
16	Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6110-TPS6110.	0.8	5
17	Unusual Cause of Stridor in an 80-Year-old Man. <i>American Journal of Medicine</i> , 2016, 129, e15-e16.	0.6	0